🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER2 Gene Mutation

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer NCT07436858Phase 11 site📍 Amsterdam The Netherlands Cancer Institute · Tests: PET imaging with ⁸⁹Zr-trastuzumab, Blood sampling for pharmacokinetics PRE-ISPY Phase I/II Oncology Platform Program NCT05868226Phase 1, Phase 210 sites📍 Birmingham📍 Phoenix📍 Aurora QuantumLeap Healthcare Collaborative · Tests: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138 Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer NCT07558733Phase 1, Phase 27 sites📍 Los Angeles📍 Lone Tree📍 Springfield Faeth Therapeutics · Tests: Serabelisib, Sapanisertib, Fulvestrant HEAT Trial (HER2 Antibody Therapy With Lutetium-177) NCT06824155EARLY Phase 15 sites📍 Kingswood📍 Macquarie Park📍 Wollongong Radiopharm Theranostics, Ltd · Tests: 177Lu-RAD202 First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) NCT05099172Phase 1, Phase 294 sites📍 Gilbert📍 Duarte📍 Atlanta Bayer · Tests: BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2, BAY2927088_formulation B_3 A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer NCT07766018Phase 219 sites📍 Chiba📍 Fukuoka📍 Fukuoka Stemline Therapeutics, Inc. · Tests: Elacestrant Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients NCT05274048Phase 13 sites📍 Palo Alto📍 Buffalo📍 Philadelphia Fox Chase Cancer Center · Tests: Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD) Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation NCT05761470Phase 21 site📍 Guangzhou Ying Lin · Tests: Camrelizumab, Fluzoparib, Nab-paclitaxel First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors NCT05768139Phase 1, Phase 265 sites📍 Los Angeles📍 San Francisco📍 Aurora Eli Lilly and Company · Tests: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration NCT05315700Phase 1, Phase 242 sites📍 Duarte📍 Huntington Beach📍 Irvine ORIC Pharmaceuticals · Tests: ORIC-114, Chemotherapy drug Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer NCT06449989n/a1 site📍 Moscow Blokhin's Russian Cancer Research Center · Tests: Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer NCT06123338Phase 210 sites📍 Boston📍 Basking Ridge📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine, 5-Fluorouracil Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer NCT06488378Phase 12 sites📍 Boston📍 Rochester Dana-Farber Cancer Institute · Tests: Axatilimab, Olaparib Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas NCT04620187Phase 213 sites📍 Atlanta📍 Chicago📍 Boston Dana-Farber Cancer Institute · Tests: Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors NCT06993844Phase 1, Phase 215 sites📍 Newport Beach📍 San Francisco📍 New Haven Ensem Therapeutics · Tests: ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination… A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) NCT07174336Phase 3363 sites📍 Anchorage📍 Chandler📍 Phoenix Eli Lilly and Company · Tests: LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib A Phase 1/1b Study of IAM1363 in HER2 Cancers NCT06253871Phase 153 sites📍 La Jolla📍 Los Angeles📍 Aurora Iambic Therapeutics, Inc · Tests: IAM1363 First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations NCT06043817Phase 1, Phase 232 sites📍 Duarte📍 Huntington Beach📍 Irvine Pierre Fabre Medicament · Tests: STX-721/PFL-721 (Escalated), STX-721/PFL-721 (3 dose levels), STX-721/PFL-721 (RP2D), STX-721/PFL-721 (Escalated) with … A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery NCT06127979NA1 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: blood draw A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations NCT06706076Phase 1, Phase 242 sites📍 Phoenix📍 Irvine📍 La Jolla BlossomHill Therapeutics · Tests: BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed, BH-30643 A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors NCT05150691Phase 1, Phase 2102 sites📍 Cerritos📍 Los Angeles📍 San Diego DualityBio Inc. · Tests: DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol NCT05722886Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Alectinib, Atezolizumab, Entrectinib, Trastuzumab in combination with pertuzumab, Vemurafenib in combination with cobim… Elacestrant in Advanced Triple Positive Breast Cancer NCT07612215Phase 1, Phase 21 site📍 New York NYU Langone Health · Tests: Elacestrant, Trastuzumab, Pertuzumab Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation NCT05696626Phase 3224 sites📍 Scottsdale📍 Tucson📍 Santa Rosa LeonaBio · Tests: Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study NCT05576389Phase 21 site📍 Beijing Peking University People's Hospital · Tests: Camrelizumab+Fluzoparib A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06760819Phase 254 sites📍 Birmingham📍 Duarte📍 Fort Myers Bayer · Tests: BAY2927088 Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer NCT07563595n/a3 sites📍 Freiburg im Breisgau📍 Paderborn📍 Ravensburg iOMEDICO AG · Tests: Elacestrant, Standard of care (Investigator Choice) Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer NCT05455619Phase 1, Phase 210 sites📍 Loma Linda📍 Newport📍 San Diego SynDevRx, Inc. · Tests: Evexomostat PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) NCT07222215Phase 21 site📍 Boston Kristina A. Fanucci · Tests: Capecitabine, Elacestrant
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy